Overview
Swedish probiotic firm's preliminary Q4 sales rise 21%, beating analyst expectations
Preliminary Q4 operating profit rises 17% with a 27% margin
Results are preliminary and will be finalized in February 2026
Outlook
BioGaia did not provide specific guidance for future quarters or full year
Result Drivers
INDIVIDUAL ORDERS - Sales were positively affected by quarterly variations for individual orders amounting to approximately SEK 35 million
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
SEK 441 mln
SEK 389.75 mln (2 Analysts)
Q4 EBIT
Beat
SEK 121 mln
SEK 96.35 mln (2 Analysts)
Q4 EBIT Margin
27.00%
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Biogaia AB is SEK135.00, about 23.4% above its February 2 closing price of SEK109.40
The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 26 three months ago
Press Release: ID:nWkr9hgTtF
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
